Justin B. Klee
Co-Chief Executive Officer at Amylyx Pharmaceuticals Inc.
Sits on 1 board. Last updated September 28, 2026
Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 4 years
- Director since
- 2023
4 years of board service in total across 1 board, counting each seat separately. Longest: Amylyx Pharmaceuticals Inc., 3 years.
Chief executive roles
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Amylyx Pharmaceuticals Inc. June 5, 202597.5%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 10, 2026 | Amylyx Pharmaceuticals Inc. | Open-market sale | −29,025 | $32.13 | $932,553 |
| Sep 10, 2026 | Amylyx Pharmaceuticals Inc. | Open-market sale | −1,439 | $33.16 | $47,710 |
| Aug 18, 2026 | Amylyx Pharmaceuticals Inc. | Grant or award | +60,039 | — | — |
| Mar 5, 2026 | Amylyx Pharmaceuticals Inc. | Grant or award | +248,865 | — | — |
| Mar 2, 2026 | Amylyx Pharmaceuticals Inc. | Open-market sale | −29,282 | $14.47 | $423,711 |
| Feb 2, 2026 | Amylyx Pharmaceuticals Inc. | Open-market sale | −15,500 | $14.69 | $227,695 |
| Jan 16, 2026 | Amylyx Pharmaceuticals Inc. | Option exercise | +2,847 | $7.57 | $21,552 |
| Jan 16, 2026 | Amylyx Pharmaceuticals Inc. | Open-market sale | −1,995 | $13.89 | $27,711 |
| Jan 15, 2026 | Amylyx Pharmaceuticals Inc. | Option exercise | +197,153 | $7.57 | $1,492,448 |
| Jan 15, 2026 | Amylyx Pharmaceuticals Inc. | Open-market sale | −136,193 | $13.58 | $1,849,501 |
| Jan 6, 2026 | Amylyx Pharmaceuticals Inc. | Open-market sale | −7,715 | $11.09 | $85,559 |
| Sep 30, 2025 | Amylyx Pharmaceuticals Inc. | Open-market sale | −29,775 | $14.37 | $427,867 |
| Sep 30, 2025 | Amylyx Pharmaceuticals Inc. | Open-market sale | −200 | $15.01 | $3,002 |
| Mar 31, 2025 | Amylyx Pharmaceuticals Inc. | Open-market sale | −21,490 | $3.46 | $74,355 |
| Mar 6, 2025 | Amylyx Pharmaceuticals Inc. | Grant or award | +180,118 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.